









Markets
/
Stocks
/
nasdaq-rani
/

Rani Therapeutics Holdings Inc

RANI

1.220USD

+0.120+10.91%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

58.49MMarket Cap

LossP/E TTM



Rani Therapeutics Holdings Inc

1.220

+0.120+10.91%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rani Therapeutics Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Rani Therapeutics Holdings Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 147 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.25.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rani Therapeutics Holdings Inc's Score

Industry at a Glance

Industry Ranking

147 / 392

Overall Ranking

292 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Rani Therapeutics Holdings Inc Highlights

StrengthsRisks

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.03M.

Fairly Valued

The company’s latest PE is -1.58, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 28.84M shares, increasing 42.37% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 5.44K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.10.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

9.250

Target Price

+740.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Rani Therapeutics Holdings Inc is 5.68, ranking 337 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.59

Change

0.09



Financials

5.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.23

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.06

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.13

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Rani Therapeutics Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Rani Therapeutics Holdings Inc is 8.76, ranking 22 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.58, which is -71.31% below the recent high of -0.45 and -286.91% above the recent low of -6.10.

Score

Industry at a Glance

Previous score

8.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 147/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Rani Therapeutics Holdings Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 11.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

9.250

Target Price

+740.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Rani Therapeutics Holdings Inc

RANI

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Rani Therapeutics Holdings Inc is 6.28, ranking 269 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.48 and the support level at 1.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.88

Change

0.4

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.029

Sell

RSI(14)

40.630

Neutral

STOCH(KDJ)(9,3,3)

27.940

Buy

ATR(14)

0.077

High Vlolatility

CCI(14)

-76.148

Neutral

Williams %R

58.904

Sell

TRIX(12,20)

-0.661

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.188

Buy

MA10

1.253

Sell

MA20

1.325

Sell

MA50

1.412

Sell

MA100

1.353

Sell

MA200

0.980

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Rani Therapeutics Holdings Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 29.56%, representing a quarter-over-quarter increase of 255.18%. The largest institutional shareholder is The Vanguard, holding a total of 5.11M shares, representing 5.24% of shares outstanding, with 119.87% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Samsara BioCapital, LLC

8.50M

RA Capital Management, LP

8.50M

The Vanguard Group, Inc.

Star Investors

884.61K

+10.62%

South Lake One, LLC

2.38M

-71.34%

Imran (Mir A)

2.14M

Orca Capital GmbH

1.89M

Invus Public Equities Advisors, LLC

1.75M

Nan Fung Life Sciences

493.58K

Citadel Advisors LLC

452.54K

+229.48%

Imran (Talat)

322.38K

+5.32%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Rani Therapeutics Holdings Inc is 1.11, ranking 350 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.45. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.